Melatonin: A pleiotropic molecule that modulates DNA damage response and repair pathways

Journal of Pineal Research

Volumn 63, Issue 1, 2017, Pages

  Majidinia, Maryam ^a   Sadeghpour, Alireza ^b,c   Mehrzadi, Saeed ^d   Reiter, Russel J ^e   Khatami, Nasrin ^b   Yousefi, Bahman ^b,f  

^a URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e University of Texas Health Science Center   (United States)

^f TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

cancer; chemotherapy; circadian rhythm; DNA; genome stability; pineal gland

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; ATM PROTEIN; ATR PROTEIN; MEDIATOR COMPLEX; MELATONIN; DNA; PROTECTIVE AGENT;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RISK; CELL CYCLE CHECKPOINT; CELL CYCLE PROGRESSION; DNA DAMAGE; DNA DAMAGE RESPONSE; DNA END JOINING REPAIR; DNA REPAIR; DNA STRUCTURE; EXCISION REPAIR; HOMOLOGOUS RECOMBINATION; HUMAN; MISMATCH REPAIR; NONHUMAN; PROTEIN PROTEIN INTERACTION; REVIEW; ANIMAL; CELL CYCLE; CIRCADIAN RHYTHM; DRUG EFFECTS; METABOLISM; MOUSE; NEOPLASM; PHYSIOLOGY; PINEAL BODY; RAT;

ANIMALS; CELL CYCLE; CIRCADIAN RHYTHM; DNA; DNA DAMAGE; DNA REPAIR; HUMANS; MELATONIN; MICE; NEOPLASMS; PINEAL GLAND; PROTECTIVE AGENTS; RATS;

EID: 85019832108     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12416     Document Type: Review

References (155)

1. Tian H, Gao Z, Li H, et al. DNA damage response–a double-edged sword in cancer prevention and cancer therapy. Cancer Lett. 2015;358:8-16.
2. Pearl LH, Schierz AC, Ward SE, Al-Lazikani B, Pearl FM. Therapeutic opportunities within the DNA damage response. Nat Rev Cancer. 2015;15:166-180.
3. Ljungman M. Targeting the DNA damage response in cancer. Chem Rev. 2009;109:2929-2950.
4. Zhang C, Peng G. Non-coding RNAs: an emerging player in DNA damage response. Mutat Res Rev Mutat Res. 2015;763:202-211.
5. Howard SM, Yanez DA, Stark JM. DNA damage response factors from diverse pathways, including DNA crosslink repair, mediate alternative end joining. PLoS Genet. 2015;11:e1004943.
6. Majidinia M, Yousefi B. DNA damage response regulation by microRNAs as a therapeutic target in cancer. DNA Repair. 2016;47:1-11.
7. Goldstein M, Kastan MB. The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu Rev Med. 2015;66:129-143.
8. Stehle JH, Saade A, Rawashdeh O, et al. A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases. J Pineal Res. 2011;51:17-43.
9. Acuña-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci. 2014;71:2997-3025.
10. Jockers R, Delagrange P, Dubocovich ML, et al. Update on melatonin receptors: IUPHAR review 20. Br J Pharmacol. 2016;173:2702-2725.
11. Reppert SM. Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J Biol Rhythms. 1997;12:528-531.
12. Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS, Slominski AT. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol. 2012;351:152-166.
13. Lacoste B, Angeloni D, Dominguez-Lopez S, et al. Anatomical and cellular localization of melatonin MT1 and MT2 receptors in the adult rat brain. J Pineal Res. 2015;58:397-417.
14. Tan D, Manchester L, Terron P, Flores L, Koppisepi S. Medical implications of melatonin: receptor-mediated and receptor-independent actions. 7 Reflections on the future of gastroenterology–unmet needs. Adv Med Sci. 2007;52:11.
15. Boutin JA. Quinone reductase 2 as a promising target of melatonin therapeutic actions. Expert Opin Ther Targets. 2016;20:303-317.
16. He B, Zhao Y, Xu L, et al. The nuclear melatonin receptor RORα is a novel endogenous defender against myocardial ischemia/reperfusion injury. J Pineal Res. 2016;60:313-326.
17. Shajari S, Laliena A, Heegsma J, Tuñón MJ, Moshage H, Faber KN. Melatonin suppresses activation of hepatic stellate cells through RORα-mediated inhibition of 5-lipoxygenase. J Pineal Res. 2015;59:391-401.
18. Carlberg C, Wiesenberg I. The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase: an unexpected relationship. J Pineal Res. 1995;18:171-178.
19. Schernhammer E, Schulmeister K. Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels? Br J Cancer. 2004;90:941-943.
20. Blask DE. Melatonin, sleep disturbance and cancer risk. Sleep Med Rev. 2009;13:257-264.
21. Hill SM, Belancio VP, Dauchy RT, et al. Melatonin: an inhibitor of breast cancer. Endocr Relat Cancer. 2015;22:R183-R204.
22. Manchester LC, Coto-Montes A, Boga JA, et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res. 2015;59:403-419.
23. Tan D-X, Manchester LC, Esteban-Zubero E, Zhou Z, Reiter RJ. Melatonin as a potent and inducible endogenous antioxidant: synthesis and metabolism. Molecules. 2015;20:18886-18906.
24. Reiter RJ, Mayo JC, Tan DX, Sainz RM, Alatorre-Jimenez M, Qin L. Melatonin as an antioxidant: under promises but over delivers. J Pineal Res. 2016;61:253-278.
25. Reiter RJ, Tan D-X, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress. J Biomed Sci. 2000;7:444-458.
26. Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004;36:1-9.
27. Hosoya N, Miyagawa K. Targeting DNA damage response in cancer therapy. Cancer Sci. 2014;105:370-388.
28. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071-1078.
29. McGowan CH, Russell P. The DNA damage response: sensing and signaling. Curr Opin Cell Biol. 2004;16:629-633.
30. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481:287-294.
31. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell. 2007;28:739-745.
32. Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316:1160-1166.
33. Wang Q, Goldstein M, Alexander P, et al. Rad17 recruits the MRE11-RAD50-NBS1 complex to regulate the cellular response to DNA double-strand breaks. EMBO J. 2014;33:862-877.
34. di Fagagna FdA. A direct role for small non-coding RNAs in DNA damage response. Trends Cell Biol. 2014;24:171-178.
35. Yan S, Sorrell M, Berman Z. Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress. Cell Mol Life Sci. 2014;71:3951-3967.
36. Broustas CG, Lieberman HB. DNA damage response genes and the development of cancer metastasis. Radiat Res. 2014;181:111-130.
37. Fokas E, Prevo R, Hammond EM, Brunner TB, McKenna WG, Muschel RJ. Targeting ATR in DNA damage response and cancer therapeutics. Cancer Treat Rev. 2014;40:109-117.
38. Zhang P, Wei Y, Wang L, et al. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol. 2014;16:864-875.
39. Stucki M, Jackson SP. γH2AX and MDC1: anchoring the DNA-damage-response machinery to broken chromosomes. DNA Repair. 2006;5:534-543.
40. Kolas NK, Chapman JR, Nakada S, et al. Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science. 2007;318:1637-1640.
41. Huen MS, Grant R, Manke I, et al. RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell. 2007;131:901-914.
42. Mailand N, Bekker-Jensen S, Faustrup H, et al. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell. 2007;131:887-900.
43. Bekker-Jensen S, Lukas C, Kitagawa R, et al. Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J Cell Biol. 2006;173:195-206.
44. Finzel A, Grybowski A, Strasen J, Cristiano E, Loewer A. Hyperactivation of ATM upon DNA-PKcs inhibition modulates p53 dynamics and cell fate in response to DNA damage. Mol Biol Cell. 2016;27:2360-2367.
45. Branzei D, Foiani M. Interplay of replication checkpoints and repair proteins at stalled replication forks. DNA Repair. 2007;6:994-1003.
46. Lambert S, Froget B, Carr AM. Arrested replication fork processing: interplay between checkpoints and recombination. DNA Repair. 2007;6:1042-1061.
47. Collis SJ, Boulton SJ. Emerging links between the biological clock and the DNA damage response. Chromosoma. 2007;116:331-339.
48. Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol. 2009;21:245-255.
49. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res. 2010;16:376-383.
50. Reiter RJ, Tan D-X, Rosales-Corral S, C Manchester L. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. Mini Rev Med Chem. 2013;13:373-384.
51. Hevia D, González-Menéndez P, Quiros-González I, et al. Melatonin uptake through glucose transporters: a new target for melatonin inhibition of cancer. J Pineal Res. 2015;58:234-250.
52. Poeggeler B, Reiter R, Tan D, Chen L, Manchester L. Melatonin: a potent, endogenous hydroxyl radical scavenger. J Pineal Res. 1993;14:57-60.
53. Tan D-X, Manchester LC, Sainz R, Mayo JC, Alvares FL, Reiter RJ. Antioxidant strategies in protection against neurodegenerative disorders. Expert Opin Ther Pat. 2003;13:1513-1543.
54. Hardeland R. Melatonin and the theories of aging: a critical appraisal of melatonin's role in antiaging mechanisms. J Pineal Res. 2013;55:325-356.
55. Zhang HM, Zhang Y. Melatonin: a well-documented antioxidant with conditional pro-oxidant actions. J Pineal Res. 2014;57:131-146.
56. Silva DGH, Ricci O, Almeida EA, Bonini-Domingos CR. Potential utility of melatonin as an antioxidant therapy in the management of sickle cell anemia. J Pineal Res. 2015;58:178-188.
57. Reiter RJ, Tan D-X, Mayo JC, Sainz RM, Leon J, Czarnocki Z. Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim Polonica-English Edition. 2003;50:1129-1146.
58. Rosales-Corral SA, Acuña-Castroviejo D, Coto-Montes A, et al. Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin. J Pineal Res. 2012;52:167-202.
59. Maarman G, Blackhurst D, Thienemann F, et al. Melatonin as a preventive and curative therapy against pulmonary hypertension. J Pineal Res. 2015;59:343-353.
60. Ma P, Yan B, Zeng Q, et al. Oral exposure of Kunming mice to diisononyl phthalate induces hepatic and renal tissue injury through the accumulation of ROS. Protective effect of melatonin. Food Chem Toxicol. 2014;68:247-256.
61. Mathes AM. Hepatoprotective actions of melatonin: possible mediation by melatonin receptors. World J Gastroenterol. 2010;16:6087-6097.
62. El-Sokkary GH, Reiter RJ, Cuzzocrea S, Caputi AP, Hassanein A-FM, Tan D-X. Role of melatonin in reduction of lipid peroxidation and peroxynitrite formation in non-septic shock induced by zymosan. Shock. 1999;12:402-408.
63. Qi W, Reiter RJ, Tan DX, Manchester LC, Siu AW, Garcia JJ. Increased levels of oxidatively damaged DNA induced by chromium (III) and H2O2: protection by melatonin and related molecules. J Pineal Res. 2000;29:54-61.
64. Melchiorri D, Reiter RJ, Sewerynek E, Hara M, Chen L, Nisticò G. Paraquat toxicity and oxidative damage: reduction by melatonin. Biochem Pharmacol. 1996;51:1095-1099.
65. Reiter R. Interactions of the pineal hormone melatonin with oxygen-centered free radicals: a brief review. Braz J Med Biol Res. 1993;26:1141-1155.
66. López-Burillo S, Tan DX, Mayo JC, Sainz RM, Manchester LC, Reiter RJ. Melatonin, xanthurenic acid, resveratrol, EGCG, vitamin C and α-lipoic acid differentially reduce oxidative DNA damage induced by Fenton reagents: a study of their individual and synergistic actions. J Pineal Res. 2003;34:269-277.
67. Yamamoto HA, Mohanan PV. Effects of melatonin on paraquat or ultraviolet light exposure-induced DNA damage. J Pineal Res. 2001;31:308-313.
68. Yamamoto HA, Mohanan PV. Preventive effect of melatonin against DNA damage induced by cyanide, kainate, glutathione/Fe3+/O2, or H2O2/Fe2+. J Pineal Res. 2001;31:314-319.
69. Wakatsuki A, Okatani Y, Lzumiya C, Lkenoue N. Melatonin protects against ischemia and reperfusion-induced oxidative lipid and DNA damage in fetal rat brain. J Pineal Res. 1999;26:147-152.
70. Morioka N, Okatani Y, Wakatsuki A. Melatonin protects against age-related DNA damage in the brains of female senescence-accelerated mice. J Pineal Res. 1999;27:202-209.
71. Lai H, Singh NP. Melatonin and N-tert-butyl-α-phenylnitrone block 60-Hz magnetic field-induced DNA single and double strand breaks in rat brain cells. J Pineal Res. 1997;22:152-162.
72. Bejarano I, Monllor F, Marchena AM, et al. Exogenous melatonin supplementation prevents oxidative stress-evoked DNA damage in human spermatozoa. J Pineal Res. 2014;57:333-339.
73. López-Burillo S, Tan DX, Rodriguez-Gallego V, et al. Melatonin and its derivatives cyclic 3-hydroxymelatonin, N1-acetyl-N2-formyl-5-methoxykynuramine and 6-methoxymelatonin reduce oxidative DNA damage induced by Fenton reagents. J Pineal Res. 2003;34:178-184.
74. Onuki J, Almeida EA, Medeiros MH, Mascio PD. Inhibition of 5-aminolevulinic acid-induced DNA damage by melatonin, N1-acetyl-n2-formyl-5-methoxykynuramine, Quercetin or Resveratrol. J Pineal Res. 2005;38:107-115.
75. Romero M, Osuna C, Garcia-Pergañeda A, Carrillo-Vico A, Guerrero JM. The pineal secretory product melatonin reduces hydrogen peroxide-induced DNA damage in U-937 cells. J Pineal Res. 1999;26:227-235.
76. Fischer TW, Kleszczyński K, Hardkop LH, Kruse N, Zillikens D. Melatonin enhances antioxidative enzyme gene expression (CAT, GPx, SOD), prevents their UVR-induced depletion, and protects against the formation of DNA damage (8-hydroxy-2’-deoxyguanosine) in ex vivo human skin. J Pineal Res. 2013;54:303-312.
77. Manda K, Ueno M, Anzai K. AFMK, a melatonin metabolite, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. J Pineal Res. 2007;42:386-393.
78. Laothong U, Pinlaor P, Hiraku Y, et al. Protective effect of melatonin against Opisthorchis viverrini-induced oxidative and nitrosative DNA damage and liver injury in hamsters. J Pineal Res. 2010;49:271-282.
79. Hsu CH, Chi BC, Casida JE. Melatonin reduces phosphine-induced lipid and DNA oxidation in vitro and in vivo in rat brain. J Pineal Res. 2002;32:53-58.
80. Shokrzadeh M, Naghshvar F, Ahmadi A, Chabra A, Jeivad F. The potential ameliorative effects of melatonin against cyclophosphamide-induced DNA damage in murine bone marrow cells. Eur Rev Med Pharmacol Sci. 2014;18:605-611.
81. Erenberk U, Dundaroz R, Gok O, et al. Melatonin attenuates phenytoin sodium-induced DNA damage. Drug Chem Toxicol. 2014;37:233-239.
82. Karamian A, Shokrzadeh M, Ahmadi A. The potential chemoprotective effects of melatonin against genotoxicity induced by diazinon in human peripheral blood lymphocytes. Toxicol Ind Health. 2016;32:360-366.
83. Wu H-J, Liu C, Duan W-X, et al. Melatonin ameliorates bisphenol A-induced DNA damage in the germ cells of adult male rats. Mutat Res. 2013;752:57-67.
84. Cadenas S, Barja G. Resveratrol, melatonin, vitamin E, and PBN protect against renal oxidative DNA damage induced by the kidney carcinogen KBrO 3. Free Radic Biol Med. 1999;26:1531-1537.
85. Uz T, Giusti P, Franceschini D, Kharlamov A, Manev H. Protective effect of melatonin against hippocampal DNA damage induced by intraperitoneal administration of kainate to rats. Neuroscience. 1996;73:631-636.
86. Tan D-X, Pöeggeler B, Reiter RJ, et al. The pineal hormone melatonin inhibits DNA-adduct formation induced by the chemical carcinogen safrole in vivo. Cancer Lett. 1993;70:65-71.
87. Liu C, Gao P, Xu S-C, et al. Mobile phone radiation induces mode-dependent DNA damage in a mouse spermatocyte-derived cell line: a protective role of melatonin. Int J Radiat Biol. 2013;89:993-1001.
88. Takada L, Junior AM, Mingoti GZ, Balieiro JCDC, Cipolla-Neto J, Coelho L. Effect of melatonin on DNA damage of bovine cumulus cells during in vitro maturation (IVM) and on in vitro embryo development. Res Vet Sci. 2012;92:124-127.
89. De Salvia R, Fiore M, Aglitti T, Festa F, Ricordy R, Cozzi R. Inhibitory action of melatonin on H2O2-and cyclophosphamide-induced DNA damage. Mutagenesis. 1999;14:107-112.
90. Qi W, Reiter RJ, Tan DX, Manchester LC, Kim SJ, Garcia JJ. Inhibitory effects of melatonin on ferric nitrilotriacetate-induced lipid peroxidation and oxidative DNA damage in the rat kidney. Toxicology. 1999;139:81-91.
91. Karbownik M, Reiter RJ, Cabrera J, Garcia JJ. Comparison of the protective effect of melatonin with other antioxidants in the hamster kidney model of estradiol-induced DNA damage. Mutat Res. 2001;474:87-92.
92. Jajte J, Zmyślony M, Palus J, Dziubałtowska E, Rajkowska E. Protective effect of melatonin against in vitro iron ions and 7 mT 50 Hz magnetic field-induced DNA damage in rat lymphocytes. Mutat Res. 2001;483:57-64.
93. Shaikh AY, Xu J, Wu Y, He L, Hsu CY. Melatonin protects bovine cerebral endothelial cells from hyperoxia-induced DNA damage and death. Neurosci Lett. 1997;229:193-197.
94. Burkhardt S, Reiter RJ, Tan D-X, Hardeland R, Cabrera J, Karbownik M. DNA oxidatively damaged by chromium (III) and H 2 O 2 is protected by the antioxidants melatonin, N 1-acetyl-N 2-formyl-5-methoxykynuramine, resveratrol and uric acid. Int J Biochem Cell Biol. 2001;33:775-783.
95. Khan S, Adhikari JS, Rizvi MA, Chaudhury NK. Radioprotective potential of melatonin against 60 Co γ-ray-induced testicular injury in male C57BL/6 mice. J Biomed Sci. 2015;22:61.
96. Santoro R, Marani M, Blandino G, Muti P, Strano S. Melatonin triggers p53Ser phosphorylation and prevents DNA damage accumulation. Oncogene. 2012;31:2931-2942.
97. Alonso-González C, González A, Martínez-Campa C, Gómez-Arozamena J, Cos S. Melatonin sensitizes human breast cancer cells to ionizing radiation by downregulating proteins involved in double-strand DNA break repair. J Pineal Res. 2015;58:189-197.
98. Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res. 2008;18:134-147.
99. Tanabe M, Tamura H, Taketani T, et al. Melatonin protects the integrity of granulosa cells by reducing oxidative stress in nuclei, mitochondria, and plasma membranes in mice. J Reprod Dev. 2015;61:35-41.
100. Chua S, Lee FY, Chiang HJ, et al. The cardioprotective effect of melatonin and exendin-4 treatment in a rat model of cardiorenal syndrome. J Pineal Res. 2016;61:438-456.
101. Chen HH, Chen YT, Yang CC, et al. Melatonin pretreatment enhances the therapeutic effects of exogenous mitochondria against hepatic ischemia–reperfusion injury in rats through suppression of mitochondrial permeability transition. J Pineal Res. 2016;61:52-68.
102. Sancar A, Lindsey-Boltz LA, Kang T-H, Reardon JT, Lee JH, Ozturk N. Circadian clock control of the cellular response to DNA damage. FEBS Lett. 2010;584:2618-2625.
103. Plaimee P, Weerapreeyakul N, Barusrux S, Johns N. Melatonin potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells. Cell Prolif. 2015;48:67-77.
104. Mediavilla M, Cos S, Sanchez-Barcelo E. Melatonin increases p53 and p21WAFl expression in MCF-7 human breast cancer cells in vitro. Life Sci. 1999;65:415-420.
105. Proietti S, Cucina A, Dobrowolny G, et al. Melatonin down-regulates MDM2 gene expression and enhances p53 acetylation in MCF-7 cells. J Pineal Res. 2014;57:120-129.
106. Cos S, Mediavilla MD, Fernández R, González-Lamuño D, Sánchez-Barceló EJ. Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro? J Pineal Res. 2002;32:90-96.
107. Martín-Renedo J, Mauriz JL, Jorquera F, Ruiz-Andrés O, González P, González-Gallego J. Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res. 2008;45:532-540.
108. Hong Y, Won J, Lee Y, et al. Melatonin treatment induces interplay of apoptosis, autophagy, and senescence in human colorectal cancer cells. J Pineal Res. 2014;56:264-274.
109. Santoro R, Mori F, Marani M, et al. Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation. Carcinogenesis. 2013;35:1051-1061.
110. Janjetovic Z, Nahmias ZP, Hanna S, et al. Melatonin and its metabolites ameliorate ultraviolet B-induced damage in human epidermal keratinocytes. J Pineal Res. 2014;57:90-102.
111. Liu R, Fu A, Hoffman AE, Zheng T, Zhu Y. Melatonin enhances DNA repair capacity possibly by affecting genes involved in DNA damage responsive pathways. BMC Cell Biol. 2013;14:1.
112. Bennukul K, Numkliang S, Leardkamolkarn V. Melatonin attenuates cisplatin-induced HepG2 cell death via the regulation of mTOR and ERCC1 expressions. World J Hepatol. 2014;6:230-242.
113. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1:22-33.
114. Sun FY, Lin X, Mao LZ, et al. Neuroprotection by melatonin against ischemic neuronal injury associated with modulation of DNA damage and repair in the rat following a transient cerebral ischemia. J Pineal Res. 2002;33:48-56.
115. Sliwinski T, Rozej W, Morawiec-Bajda A, Morawiec Z, Reiter R, Blasiak J. Protective action of melatonin against oxidative DNA damage—chemical inactivation versus base-excision repair. Mutat Res. 2007;634:220-227.
116. Martínez-Alfaro M, Hernández-Cortés D, Wrobel K, et al. Effect of melatonin administration on DNA damage and repair responses in lymphocytes of rats subchronically exposed to lead. Mutat Res. 2012;742:37-42.
117. Kontek R, Nowicka H. The modulatory effect of melatonin on genotoxicity of irinotecan in healthy human lymphocytes and cancer cells. Drug Chem Toxicol. 2013;36:335-342.
118. Majsterek I, Gloc E, Blasiak J, Reiter RJ. A comparison of the action of amifostine and melatonin on DNA-damaging effects and apoptosis induced by idarubicin in normal and cancer cells. J Pineal Res. 2005;38:254-263.
119. Junttila MR, Evan GI. p53—a Jack of all trades but master of none. Nat Rev Cancer. 2009;9:821-829.
120. Pariente R, Pariente JA, Rodríguez AB, Espino J. Melatonin sensitizes human cervical cancer HeLa cells to cisplatin-induced cytotoxicity and apoptosis: effects on oxidative stress and DNA fragmentation. J Pineal Res. 2016;60:55-64.
121. Kim JH, Jeong SJ, Kim B, Yun SM, Choi DY, Kim SH. Melatonin synergistically enhances cisplatin-induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK-OV-3 cells. J Pineal Res. 2012;52:244-252.
122. Koşar PA, Nazıroğlu M, Övey İS, Çiğ B. Synergic effects of doxorubicin and melatonin on apoptosis and mitochondrial oxidative stress in MCF-7 breast cancer cells: involvement of TRPV1 channels. J Membr Biol. 2016;249:129-140.
123. Casado-Zapico S, Rodriguez-Blanco J, García-Santos G, et al. Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human Ewing sarcoma cancer cells: potentiation of the extrinsic apoptotic pathway. J Pineal Res. 2010;48:72-80.
124. Tripathi D, Jena G. Effect of melatonin on the expression of Nrf2 and NF-κB during cyclophosphamide-induced urinary bladder injury in rat. J Pineal Res. 2010;48:324-331.
125. Um HJ, Kwon TK. Protective effect of melatonin on oxaliplatin-induced apoptosis through sustained Mcl-1 expression and anti-oxidant action in renal carcinoma Caki cells. J Pineal Res. 2010;49:283-290.
126. Maity P, Bindu S, Dey S, et al. Melatonin reduces indomethacin-induced gastric mucosal cell apoptosis by preventing mitochondrial oxidative stress and the activation of mitochondrial pathway of apoptosis. J Pineal Res. 2009;46:314-323.
127. Yu L, Liang H, Dong X, et al. Reduced silent information regulator 1 signaling exacerbates myocardial ischemia–reperfusion injury in type 2 diabetic rats and the protective effect of melatonin. J Pineal Res. 2015;59:376-390.
128. Tian YM, Li PP, Jiang XF, Zhang GY, Dai YR. Rejuvenation of degenerative thymus by oral melatonin administration and the antagonistic action of melatonin against hydroxyl radical-induced apoptosis of cultured thymocytes in mice. J Pineal Res. 2001;31:214-221.
129. Mayo JC, Sainz RM, Uria H, Antolin I, Esteban MM, Rodriguez C. Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease. J Pineal Res. 1998;24:179-192.
130. Zhou L, Chen X, Liu T, et al. Melatonin reverses H2O2-induced premature senescence in mesenchymal stem cells via the SIRT1-dependent pathway. J Pineal Res. 2015;59:190-205.
131. Manda K, Ueno M, Anzai K. Melatonin mitigates oxidative damage and apoptosis in mouse cerebellum induced by high-LET 56Fe particle irradiation. J Pineal Res. 2008;44:189-196.
132. Guha M, Maity P, Choubey V, Mitra K, Reiter RJ, Bandyopadhyay U. Melatonin inhibits free radical-mediated mitochondrial-dependent hepatocyte apoptosis and liver damage induced during malarial infection. J Pineal Res. 2007;43:372-381.
133. Fischer T, Zmijewski M, Wortsman J, Slominski A. Melatonin maintains mitochondrial membrane potential and attenuates activation of initiator (casp-9) and effector caspases (casp-3/casp-7) and PARP in UVR-exposed HaCaT keratinocytes. J Pineal Res. 2008;44:397-407.
134. Feng Z, Zhang JT. Melatonin reduces amyloid β-induced apoptosis in pheochromocytoma (PC12) cells. J Pineal Res. 2004;37:257-266.
135. Amin AH, El-Missiry MA, Othman AI. Melatonin ameliorates metabolic risk factors, modulates apoptotic proteins, and protects the rat heart against diabetes-induced apoptosis. Eur J Pharmacol. 2015;747:166-173.
136. Kunduzova OR, Escourrou G, Seguelas M-H, et al. Prevention of apoptotic and necrotic cell death, caspase-3 activation, and renal dysfunction by melatonin after ischemia/reperfusion. FASEB J. 2003;17:872-874.
137. Zupančič D, Jezernik K, Vidmar G. Effect of melatonin on apoptosis, proliferation and differentiation of urothelial cells after cyclophosphamide treatment. J Pineal Res. 2008;44:299-306.
138. Osborne NN, Nash MS, Wood J. Melatonin counteracts ischemia-induced apoptosis in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1998;39:2374-2383.
139. Wang FW, Wang Z, Zhang YM, et al. Protective effect of melatonin on bone marrow mesenchymal stem cells against hydrogen peroxide-induced apoptosis in vitro. J Cell Biochem. 2013;114:2346-2355.
140. Ling X, Zhang L-M, Lu S-D, Li X-J, Sun F-Y. Protective effect of melatonin on injured cerebral neurons is associated with bcl-2 protein over-expression. Zhongguo Yao Li Xue Bao. 1999;20:409-414.
141. Yu L, Sun Y, Cheng L, et al. Melatonin receptor-mediated protection against myocardial ischemia/reperfusion injury: role of SIRT1. J Pineal Res. 2014;57:228-238.
142. Uguz AC, Cig B, Espino J, et al. Melatonin potentiates chemotherapy-induced cytotoxicity and apoptosis in rat pancreatic tumor cells. J Pineal Res. 2012;53:91-98.
143. Lissoni P, Rovelli F, Brivio F, Fumagalli L, Brera G. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients. In Vivo. 2008;22:397-400.
144. Witt-Enderby PA, Radio NM, Doctor JS, Davis VL. Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. J Pineal Res. 2006;41:297-305.
145. Bubenik GA. Review: gastrointestinal melatonin: localization, function, and clinical relevance. Dig Dis Sci. 2002;47:2336-2348.
146. Bizzarri M, Proietti S, Cucina A, Reiter RJ. Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opin Ther Targets. 2013;17:1483-1496.
147. Espino J, Pariente JA, Rodríguez AB. Oxidative stress and immunosenescence: therapeutic effects of melatonin. Oxid Med Cell Longev. 2012;2012:1-9.
148. Karasek M. Does melatonin play a role in aging processes? J Physiol Pharmacol. 2007;58:105-113.
149. Srinivasan V, Pandi-Perumal S, Cardinali D, Poeggeler B, Hardeland R. Melatonin in Alzheimer's disease and other neurodegenerative disorders. Behav Brain Funct. 2006;2:15.
150. Jung B, Ahmad N. Melatonin in cancer management: progress and promise. Can Res. 2006;66:9789-9793.
151. Prieto-Domínguez N, Ordóñez R, Fernández A, et al. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. J Pineal Res. 2016;61:396-407.
152. Yun M, Kim E-O, Lee D, et al. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib. Cell Physiol Biochem. 2014;34:865-872.
153. Yamanishi M, Narazaki H, Asano T. Melatonin overcomes resistance to clofarabine in two leukemic cell lines by increased expression of deoxycytidine kinase. Exp Hematol. 2015;43:207-214.
154. Buyukavci M, Özdemir O, Buck S, Ravindranath Y, Savasan S. Effect of melatonin on the cytotoxicity of chemotherapeutic drugs in human leukemia cells. In Vivo. 2011;25:405-409.
155. Granzotto M, Rapozzi V, Decorti G, Giraldi T. Effects of melatonin on doxorubicin cytotoxicity in sensitive and pleiotropically resistant tumor cells. J Pineal Res. 2001;31:206-213.